Skip to main content

Table 1 Patient characteristics when tacrolimus treatment was started

From: Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

  Overall (N = 87) Oral (N = 22) Intravenous (N = 65) p value
Female/male 39 (45%)/48 (55%) 8 (36%)/14 (64%) 31 (48%)/34 (52%) 0.46
Age (years) 40 (24–50) 39 (25–49) 40 (24–52) 0.57
Disease duration (years) 2.9 (1.0–8.3) 2.5 (0.8–11.5) 3.0 (1.2–7.8) 0.95
Disease type: extensive /left-sided 71 (82%)/16 (18%) 16 (73%)/6 (27%) 55 (85%)/10 (15%) 0.18
Body mass index 19.4 (16.9–22.6) 20.1 (16.6–23.6) 19.4 (16.8–22.1) 0.8
Lichtiger index 13 (12–15) 12 (12–14) 14 (12–15) 0.09
Endoscopic score (UCEIS) 6 (5–7) 6 (4–8) 6 (5–7) 0.86
Hemoglobin (g/dL) 11.3 (9.7–12.8) 12.0 (10.3–13.4) 11.3 (9.2–12.8) 0.13
Albumin (g/dL) 3.2 (2.6–3.7) 3.2 (2.6–3.8) 3.2 (2.6–3.7) 0.74
C-reactive protein (mg/dL) 3.1 (1.5–9.0) 4.2 (2.2–11.8) 2.8 (1.1–7.4) 0.06
Erythrocyte sedimentation rate (mm/h) 53 (32–81) 56 (31–73) 48 (35–82) 0.87
Creatinine (mg/dL) 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.83
Corticosteroid refractory/dependent 66 (76%) / 21 (24%) 16 (73%) / 6 (27%) 50 (77%) / 15 (23%) 0.45
Biologic agent naive 61 (70%) 14 (64%) 47 (72%) 0.31
  1. Numerical data shows median value with interquartile range. Continuous variables were compared using the Mann–Whitney U test and categorical variables were compared using Fischer’s exact test
  2. UCEIS ulcerative colitis endoscopic index of severity